
1011119-79-1);
2-[(1-acetyl-2,3-dihydro-1H-indol-5-yl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 949443-90-7);
1-(1H-indol-3-yl)-2-phenyl-2-[(1-propyl-4-piperidinyl)amino]-ethanone (CAS nr. 941047-24-1);
2-(cyclopentylamino)-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 931079-25-3);
1-(1H-indol-3-yl)-2-[(4-methylphenyl)amino]-2-phenyl-ethanone (CAS nr. 931016-79-4);
2-(cyclopropylamino)-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 931000-99-6);
2-[(3,4-dihydro-2H-1-benzothiopyran-4-yl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 924713-60-0)**;**
2-[(3,4-dimethoxyphenyl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 924712-67-4)**;**
2-ethoxy-5-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-N,N-dimethyl-benzenesulfonamide (CAS nr. 920883-17-6);
6-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-2-methyl-2H-1,4-benzoxazin-3(4H)-one (CAS nr. 920834-07-7);
2-[(3,4-dihydro-2H-1-benzopyran-4-yl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 920819-87-0)**;**
4-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-benzeneacetonitrile (CAS nr. 920669-36-9)**;**
1-(1H-indol-3-yl)-2-[(4-methoxyphenyl)amino]-2-phenyl-ethanone (CAS nr. 920601-77-0)**;**
1-(1H-indol-3-yl)-2-phenyl-2-(1,1-dioxotetrahydrothiophen-3-ylamino)ethanone (CAS nr. 878619-92-2);
2-[[3-(hydroxymethyl)phenyl]amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 875166-36-2)**;**
2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 874669-99-5)**;**
2-[4-[[2-(1H-indol-3-yl)-2-oxo-1-phenyl-ethyl]amino]phenyl]-N,N-dimethyl-acetamide;
4-[[2-(1H-indol-3-yl)-2-oxo-1-phenyl-ethyl]amino]-1,5-dimethyl-2-phenyl-pyrazol-3-one;
(2S)-2-(1,3-benzodioxol-5-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone;
(2S)-2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone;

(2S)-2-anilino-1-(1H-indol-3-yl)-2-phenylethanone;
(2S)-1-(1H-indol-3-yl)-2-(3-methylanilino)-2-phenylethanone;
(2S)-1-(1H-indol-3-yl)-2-(3-methoxyanilino)-2-phenylethanone;
(2S)-1-(1H-indol-3-yl)-2-(4-methylanilino)-2-phenylethanone;
(2S)-1-(1H-indol-3-yl)-2-(4-methoxyanilino)-2-phenylethanone;
Methyl 4-[[(1S)-2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]benzoate;
(2S)-1-(1H-indol-3-yl)-2-phenyl-2-(3,4,5-trimethoxyanilino)ethanone;
(2S)-2-(4-ethoxy-3-methoxyanilino)-1-(1H-indol-3-yl)-2-phenylethanone;
2-[4-[[(1S)-2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]phenyl]acetonitrile;
(2S)-2-(4-fluoroanilino)-1-(1H-indol-3-yl)-2-phenylethanone;
(2R)-2-[(1-acetyl-2,3-dihydroindol-5-yl)amino]-1-(1H-indol-3-yl)-2-phenylethanone;
(2S)-2-(3,4-dihydro-2H-1,5-benzodioxepin-7-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone;
(2R)-2-(4-fluoroanilino)-1-(1H-indol-3-yl)-2-phenyl-ethanone;
3,4-dihydro-6-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-2(1H)-quinolinone (CAS nr. 1277962-26-1);
2-[(3-(hydroxymethyl)-4-methoxyphenyl)amino]-1-(1H-indol-3-yl)-2-phenylethanone; or
2-(1,3-benzodioxol-5-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone.















CLAIMS

1. A compound, characterized for being of formula (B),





(B)


wherein

- the moiety  is selected from , , , , , , , , , , , , and ; wherein the wavy line (〰) indicates the point of attachment to the carbonyl of the main formula (B); wherein said moiety is unsubstituted;

- cycle B is selected from







wherein the wavy line (〰) indicates the point of attachment to the carbon atom of the main formula (B), and wherein the depicted cycles may be optionally substituted with one, two, or three Z^{1a};

- R^1 is selected from C_{3-7}cycloalkyl, aryl, heterocycle;

and wherein said C_{3-7}cycloalkyl, aryl, and heterocycle, are optionally substituted with one, two, or three Z^{1b};

- R^2 is hydrogen;

- each Z^{1a} is independently selected from the group consisting of halogen, hydroxyl, sulfhydryl, -OZ^2, -O-C(=O)Z^3, =O, -SZ^2, =S, -S(=O)Z^2, -$S(=O)_2Z^3$, -$S(=O)_2NZ^4Z^5$, trifluoromethoxy, nitro, -NZ^4Z^5, -$NZ^4S(=O)_2Z^2$, -$NZ^4C(=O)Z^2$, -$NZ^4C(=O)NZ^4Z^5$, cyano, -C(=O)Z^3, -C(=O)OZ^2, -C(=O)NZ^4Z^5, -C(=O)H, heteroC_{1-6}alkyl, aryl, heterocycle, and heterocycle-C_{1-6}alkyl;

and wherein said heteroC_{1-6}alkyl, aryl, heterocycle, and heterocycle-C_{1-6}alkyl, are optionally substituted with one, two, or three substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, -OCF_3, -O-C(O)Me, cyano, nitro, -C(O)OH, -C(O)OC_{1-6}alkyl, -NH_2, -$NHCH_3$; -$N(CH_3)_2$, -NH-C(=O)O-C_{1-4}alkyl; -$S(O)_2C_{1-4}$alkyl, and –O-C_{1-6}alkyl;

- each Z^{1b} is independently selected from the group consisting of halogen, hydroxyl, sulfhydryl, -OZ^2, -O-C(=O)Z^3, =O, -SZ^2, =S, -S(=O)Z^2, -$S(=O)_2Z^3$, -$S(=O)_2NZ^4Z^5$, trifluoromethyl, trifluoromethoxy, nitro, -NZ^4Z^5, -$NZ^4C(=O)NZ^4Z^5$, cyano, -C(=O)Z^3, -C(=O)OZ^2, -C(=O)H, C_{1-6}alkyl, heteroC_{1-6}alkyl, aryl, and heterocycle;

and wherein said C_{1-6}alkyl, heteroC_{1-6}alkyl, aryl, and heterocycle, are optionally substituted with one, two, or three substituents selected from hydroxyl, halogen, -SH, =S, trifluoromethyl, -OCF_3, -O-C(O)Me, cyano, nitro, -C(O)OH, -C(O)OC_{1-6}alkyl, -NH_2, -$NHCH_3$; -$N(CH_3)_2$, -NH-C(=O)O-C_{1-4}alkyl; -$S(O)_2C_{1-4}$alkyl, and –O-C_{1-6}alkyl;

- each Z^2 is independently selected from C_{1-6}alkyl, aryl, and heterocycle;

wherein said C_{1-6}alkyl, aryl, heterocycle, are optionally substituted with one, two, or three substituents selected from hydroxyl, =O, halogen, -SH, =S, trifluoromethyl, difluoromethyl, -O-C_{1-6}alkyl, -OCF_3, -$S(=O)_2C_{1-4}$alkyl, cyano, nitro, -C(=O)OH, -C(=O)O-C_{1-4}alkyl, -NH_2, and -$N(CH_3)_2$, pyrrolidinyl, piperidinyl, and piperazinyl;

- each Z^3 is independently selected from hydroxyl, C_{1-6}alkyl, aryl, and heterocycle;

wherein said C_{1-6}alkyl, aryl, and heterocycle are optionally substituted with one, two, or three substituents selected from C_{1-6}alkyl and -$N(CH_3)_2$;

- each Z^4 and Z^5 is independently selected from hydrogen, C_{1-6}alkyl, aryl, C_{3-7}cycloalkyl, and heterocycle;

or 1-(1H-indol-4-yl)-2-(3-methoxyanilino)-2-phenyl-ethanone;

or 1-(4-isoquinolyl)-2-(3-methoxyanilino)-2-phenyl-ethanone;

or 1-(1H-indol-3-yl)-2-(3-methoxy-N-methyl-anilino)-2-phenyl-ethanone;

or 3-[[2-(1H-indol-3-yl)-2-oxo-1-phenyl-ethyl]amino]-N,N-dimethyl-benzamide;

or 2-[2-furylmethyl(methyl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone;

or N-[2-(1H-indol-3-yl)-2-oxo-1-phenyl-ethyl]-2-(dimethylamino)-N-(3-methoxyphenyl)acetamide;

and stereo-isomers or tautomers, solvates, or salts in particular pharmaceutically acceptable salts thereof;

wherein the term “alkyl” as used herein means a normal, secondary, or tertiary, linear or cyclic or a combination of linear and cyclic, branched or straight hydrocarbon with no site of unsaturation,

wherein the term “heteroalkyl” as used herein refers to an acyclic alkyl wherein one or more carbon atoms are replaced by an oxygen, nitrogen or sulphur atom, with the proviso that said chain may not contain two adjacent O atoms or two adjacent S atoms;

wherein the term “heterocycle” means a saturated, unsaturated, or aromatic ring system of 3 to

18 atoms including at least one N, O, S or P;

the term “aryl” means an aromatic hydrocarbon radical of 6-20 carbon atoms derived by the removal of hydrogen from a carbon atom of a parent aromatic ring system,

with the proviso that compound per se of formula (B) is not:

3-(2-(1H-indol-3-yl)-2-oxo-1-phenylethylamino)benzenesulfonamide (CAS nr. 1211427-21-2);

2-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone (CAS nr. 1090733-87-1);

1-(1H-indol-3-yl)-2-phenyl-2-(m-tolylamino)ethanone (CAS nr. 1252467-88-1);

2-(4-ethoxy-3-(hydroxymethyl)phenylamino)-1-(1H-indol-3-yl)-2-phenylethanone (CAS nr. 1241127-58-1);

1-(1H-indol-3-yl)-2-[(6-methoxy-3-pyridinyl)amino]-2-phenyl-ethanone (CAS nr. 1181884-55-8);

1-(1H-indol-3-yl)-2-[(1-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-ethanone (CAS nr. 1134766-19-0);

2-[(3,5-dimethoxyphenyl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 1030232-46-2);

1-(1H-indol-3-yl)-2-phenyl-2-(phenylamino)-ethanone (CAS nr. 1030214-83-5);

1-(1H-indol-3-yl)-2-[[6-(4-morpholinyl)-3-pyridinyl]amino]-2-phenyl-ethanone (CAS nr. 1030212-41-9);

2-(3-(difluoromethoxy)-4-methoxyphenylamino)-1-(1H-indol-3-yl)-2-phenylethanone (CAS nr. 1015662-06-2);

1-(1H-indol-3-yl)-2-phenyl-2-[(3,4,5-trimethoxyphenyl)amino]-ethanone (CAS nr. 1014535-82-0);

2-[(4-fluorophenyl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 1014493-63-0);

2-[(4-ethoxy-3-methoxyphenyl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 1014422-80-0);

1-[4-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-2-methoxyphenyl]-2-pyrrolidinone (CAS nr. 1011119-79-1);

2-[(1-acetyl-2,3-dihydro-1H-indol-5-yl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 949443-90-7);

1-(1H-indol-3-yl)-2-phenyl-2-[(1-propyl-4-piperidinyl)amino]-ethanone (CAS nr. 941047-24-1);

2-(cyclopentylamino)-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 931079-25-3);

1-(1H-indol-3-yl)-2-[(4-methylphenyl)amino]-2-phenyl-ethanone (CAS nr. 931016-79-4);

2-(cyclopropylamino)-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 931000-99-6);

2-[(3,4-dihydro-2H-1-benzothiopyran-4-yl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 924713-60-0)**;**

2-[(3,4-dimethoxyphenyl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 924712-67-4)**;**

2-ethoxy-5-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-N,N-dimethyl-benzenesulfonamide (CAS nr. 920883-17-6);

6-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-2-methyl-2H-1,4-benzoxazin-3(4H)-one (CAS

nr. 920834-07-7);
2-[(3,4-dihydro-2H-1-benzopyran-4-yl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 920819-87-0);
4-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-benzeneacetonitrile (CAS nr. 920669-36-9);
1-(1H-indol-3-yl)-2-[(4-methoxyphenyl)amino]-2-phenyl-ethanone (CAS nr. 920601-77-0);
1-(1H-indol-3-yl)-2-phenyl-2-(1,1-dioxotetrahydrothiophen-3-ylamino)ethanone (CAS nr. 878619-92-2);
2-[[3-(hydroxymethyl)phenyl]amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 875166-36-2);
2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-1-(1H-indol-3-yl)-2-phenyl-ethanone (CAS nr. 874669-99-5);
2-[4-[[2-(1H-indol-3-yl)-2-oxo-1-phenyl-ethyl]amino]phenyl]-N,N-dimethyl-acetamide;
4-[[2-(1H-indol-3-yl)-2-oxo-1-phenyl-ethyl]amino]-1,5-dimethyl-2-phenyl-pyrazol-3-one;
(2S)-2-(1,3-benzodioxol-5-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone;
(2S)-2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone;
(2S)-2-anilino-1-(1H-indol-3-yl)-2-phenylethanone;
(2S)-1-(1H-indol-3-yl)-2-(3-methylanilino)-2-phenylethanone;
(2S)-1-(1H-indol-3-yl)-2-(3-methoxyanilino)-2-phenylethanone;
(2S)-1-(1H-indol-3-yl)-2-(4-methylanilino)-2-phenylethanone;
(2S)-1-(1H-indol-3-yl)-2-(4-methoxyanilino)-2-phenylethanone;
Methyl 4-[[(1S)-2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]benzoate;
(2S)-1-(1H-indol-3-yl)-2-phenyl-2-(3,4,5-trimethoxyanilino)ethanone;
(2S)-2-(4-ethoxy-3-methoxyanilino)-1-(1H-indol-3-yl)-2-phenylethanone;
2-[4-[[(1S)-2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]phenyl]acetonitrile;
(2S)-2-(4-fluoroanilino)-1-(1H-indol-3-yl)-2-phenylethanone;
(2R)-2-[(1-acetyl-2,3-dihydroindol-5-yl)amino]-1-(1H-indol-3-yl)-2-phenylethanone;
(2S)-2-(3,4-dihydro-2H-1,5-benzodioxepin-7-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone;
(2R)-2-(4-fluoroanilino)-1-(1H-indol-3-yl)-2-phenyl-ethanone;
3,4-dihydro-6-[[2-(1H-indol-3-yl)-2-oxo-1-phenylethyl]amino]-2(1H)-quinolinone (CAS nr. 1277962-26-1);
2-[(3-(hydroxymethyl)-4-methoxyphenyl)amino]-1-(1H-indol-3-yl)-2-phenylethanone; or
2-(1,3-benzodioxol-5-ylamino)-1-(1H-indol-3-yl)-2-phenylethanone.

2. The compound according to claim 1, wherein

- each Z^{1a} is independently selected from the group consisting of halogen, hydroxyl, $-OZ^2$, $-O-C(=O)Z^3$, =O, $-S(=O)_2Z^3$, $-S(=O)_2NZ^4Z^5$, trifluoromethoxy, $-NZ^4Z^5$, $-NZ^4C(=O)Z^2$, cyano, $-C(=O)Z^3$, $-C(=O)OZ^2$, $-C(=O)NZ^4Z^5$, heteroC_{1-6}alkyl, aryl, heterocycle, and heterocycle-C_{1-6}alkyl;

and wherein said aryl, and heterocycle are optionally substituted with one, two, or three substituents selected from hydroxyl, =O, -O-C(O)Me, cyano, -C(O)OH, -C(O)OC$_{1-6}$alkyl, -NH$_2$, -NHCH$_3$; -N(CH$_3$)$_2$, -NH-C(=O)O-C$_{1-4}$alkyl; -S(O)$_2$C$_{1-4}$alkyl, and –O-C$_{1-6}$alkyl;

- each Z^{1b} is independently selected from the group consisting of halogen, hydroxyl, -OZ^2, -O-C(=O)Z^3, =O, -S(=O)$_2Z^3$, -S(=O)$_2$NZ^4Z^5, trifluoromethyl, trifluoromethoxy, -NZ^4Z^5, cyano, -C(=O)Z^3, -C(=O)OZ^2, C$_{1-6}$alkyl, heteroC$_{1-6}$alkyl, aryl, and heterocycle;

and wherein said C$_{1-6}$alkyl, aryl, and heterocycle are optionally substituted with one, two, or three substituents selected from hydroxyl, -O-C(O)Me, cyano, -C(O)OH, -C(O)OC$_{1-6}$alkyl, -NH$_2$, -NHCH$_3$; -N(CH$_3$)$_2$, -NH-C(=O)O-C$_{1-4}$alkyl; -S(O)$_2$C$_{1-4}$alkyl, and –O-C$_{1-6}$alkyl;

- each Z^2 is independently selected from C$_{1-6}$alkyl, aryl;

wherein said C$_{1-6}$alkyl, and aryl, are optionally substituted with one, two, or three substituents selected from hydroxyl, halogen, difluoromethyl, -O-C$_{1-6}$alkyl, -S(=O)$_2$C$_{1-4}$alkyl, -C(=O)OH, -C(=O)O-C$_{1-4}$alkyl, -NH$_2$, and -N(CH$_3$)$_2$, pyrrolidinyl, piperidinyl, and piperazinyl;




- each Z^3 is independently selected from hydroxyl, C$_{1-6}$alkyl, and heterocycle;



wherein said C$_{1-6}$alkyl and heterocycle are optionally substituted with one, two, or three substituents selected from C$_{1-6}$alkyl and -N(CH$_3$)$_2$;








- each Z^4 and Z^5 is independently selected from hydrogen, C$_{1-6}$alkyl, and C$_{3-7}$cycloalkyl;


and stereo-isomers or tautomers, solvates, or salts in particular pharmaceutically acceptable salts thereof;

3. The compound of formula (B) according to claim 1, wherein

- the moiety  is selected from , ,

 , and  ; wherein said moiety is unsubstituted;

- cycle B is selected from  ,  ,  ,  ,  ,  , and  ; wherein the wavy line (〰) indicates the point of attachment to the carbon atom of the main formula (B), and wherein the depicted cycles may be optionally substituted with one, two, or three Z^{1a};

- R^1 is a moiety selected from ; which moiety is optionally substituted with one, two, or three Z^{1b};

- Z^{1b}, is selected from the group consisting of halogen, hydroxyl, $-OZ^2$, =O, $-S(=O)_2Z^3$, $-S(=O)_2NZ^4Z^5$, trifluoromethyl, trifluoromethoxy, $-NZ^4Z^5$, cyano, $-C(=O)Z^3$, $-C(=O)OZ^2$, C_{1-6}alkyl, aryl, and heterocycle;

  and wherein said C_{1-6}alkyl, aryl, and heterocycle are optionally substituted with one, two, or three substituents selected from hydroxyl, -O-C(O)Me, cyano, -C(O)OH,, $-NHCH_3$; $-N(CH_3)_2$, $-S(O)_2C_{1-4}$alkyl, and $–O-C_{1-6}$alkyl;

- R^2 is hydrogen;
- each Z^{1a} is independently selected from the group consisting of halogen, hydroxyl, $-OZ^2$, $-O-C(=O)Z^3$, =O, $-S(=O)_2Z^3$, $-S(=O)_2NZ^4Z^5$, trifluoromethoxy, $-NZ^4Z^5$, $-NZ^4C(=O)Z^2$, $-NZ^4C(=O)-OZ^2$, cyano, $-C(=O)Z^3$, $-C(=O)OZ^2$, $-C(=O)NZ^4Z^5$, heteroC_{1-6}alkyl, aryl, heterocycle, and heterocycle-C_{1-6}alkyl;

  wherein said aryl, and heterocycle are optionally substituted with one, two, or three substituents selected from hydroxyl, =O, -O-C(O)Me, cyano, -C(O)OH, $-C(O)OC_{1-6}$alkyl, $-NH_2$, $-NHCH_3$; $-N(CH_3)_2$, $-NH-C(=O)O-C_{1-4}$alkyl, morpholinyl, $-S(O)_2C_{1-4}$alkyl, and $–O-C_{1-6}$alkyl;

- Z^2 is independently selected from C_{1-6}alkyl, and aryl;

  wherein said C_{1-6}alkyl, and aryl, are optionally substituted with one, two, or three substituents selected from hydroxyl, halogen, difluoromethyl, $-O-C_{1-6}$alkyl, $-S(=O)_2C_{1-4}$alkyl, -C(=O)OH, $-C(=O)O-C_{1-4}$alkyl, $-NH_2$, and $-N(CH_3)_2$, pyrrolidinyl, piperidinyl, and piperazinyl;


- Z^3 is independently selected from hydroxyl, C_{1-6}alkyl, and heterocycle;

  wherein said C_{1-6}alkyl and heterocycle are optionally substituted with one, two, or three

substituents selected from C_{1-6}alkyl and -$N(CH_3)_2$;

- each Z^4 and Z^5 is independently selected from hydrogen, C_{1-6}alkyl, and C_{3-7}cycloalkyl.


4. The compound according to any one of claims 1 or 2, wherein the compound has the structure of formula (G),



(G)

wherein cycle B, R^1, and $R^2$are as defined in any one of claims 1 or 2, R^4 is hydrogen and X^1 is N or CH, and n is selected from 0.

5. The compound according to any one of claims 1 or 2 wherein the compound has the structure of formula (H),




(H)

wherein

- cycle B, and each Z^{1b} independently, are as defined in any one of claims 1 or 2;
- m is selected from 0, 1, 2, and 3;
- n is 0; and
  wherein X^2 is NH and X^1 is CH or N, or
  X^2 is S and X^1 is CH, or
- X^2 is O and X^1 is N.

6. The compound according to any one of claims 1 or 2, wherein the compound has the structure of formula (I),





(I)


wherein

- each Z^{1b} independently, are as defined in any one of claims 1 or 2;
- cycle B is as defined in any one of claims 1 or 2;
- n is 0; and
- m is selected from 0, 1, 2, and 3.









7. The compound according to claim 1, wherein

the moiety  is .

8. The compound according to claim 1 wherein the compound has the structure of formula (F1)



(F1)

and the bicyclic moiety is selected from , , , , , , , and .

9. The compound according to any one of claims 1-8, wherein the carbon atom substituted with cycle B is in the R configuration.

10. The compound according to any one of claims 1-8, wherein the carbon atom substituted with cycle B is in the S configuration.

11. A compound according to any one of claims 1-10, for use as a medicine.


12. A compound according to any one of claims 1-10, for use in the prevention or treatment of a flavivirus infection in an animal, mammal or human.


13. Use of a compound according to any one of claims 1-10, in the manufacture of a medicament for prevention or treatment of a Flaviviral infection in an animal, mammal or human.

14. The compound for use according to claim 12 or the use according to claim 13, wherein the flavivirus infection is an infection with a Dengue virus or a yellow fever virus.



15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient an effective amount of the compound according to any one of claims 1-10 or a pharmaceutically acceptable salt thereof.


16. A method for the preparation of the compound according to any one of claims 1-10 comprising the step of

– reacting compound of formula (X1) with the amine R^1R^2NH in a suitable solvent, wherein cycle A corresponds to moiety  of formula (B) as defined in claims 1-10, cycle B, R^1, and R^2 have the meaning according to any one of claims 1-10, and LG is a leaving group, preferably selected from chlorine, bromine, and iodine; or



(X1)

– reacting the imine of formula (X2) with an aldehyde of formula (X3) in the presence of a catalyst and a suitable solvent to obtain compound of formula (A1), wherein cycle A of formula  corresponds to moiety  of formula (B) as defined in claims 1-10, cycle B, and R^1, have the meaning according to any one of claims 1-10, and provided that in cycle A of formulae (X3) and (A1), a carbon atom is binding to the carbonyl.



(X2) (X3) (A1)

17. Use of an effective amount of a compound according to any one of claims 1-10 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treatment or prevention of Flaviviral infections in humans, wherein the medicament is to be optionally administered in combination with one or more other medicines, to a patient in need thereof, substantially as described in the specification.

18. The use according to claim 17, wherein the Flaviviral infection is an infection by the Dengue virus or yellow fever virus.